This article was originally published in The Tan Sheet
Procter & Gamble estimates first quarter earnings of $.72 per share, an increase of 14% versus the prior-year quarter, company announces during the Prudential Back to School Consumer Conference Sept. 9. The marketer of Crest oral care products also expects organic sales growth in Q1 to be in the 4% to 6% range, excluding the estimated impacts of acquisitions and divestitures as well as foreign exchange. The estimates are based in part on "robust" first-quarter initiatives, the firm notes...
You may also be interested in...
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.